A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : sEH / soluble epoxide hydrolase

[Related PubMed/MEDLINE]
Total Number of Papers: 874
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   sEH  (>> Co-occurring Abbreviation)
Long Form:   soluble epoxide hydrolase
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2023 Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors. ---
2  2023 Direct targeting of sEH with alisol B alleviated the apoptosis, inflammation, and oxidative stress in cisplatin-induced acute kidney injury. AKI, CIS
3  2023 Soluble epoxide hydrolase and TRPC3 channels jointly contribute to homocysteine-induced cardiac hypertrophy: Interrelation and regulation by C/EBPβ. EETs, TPPU, TRPC3
4  2023 Structure-Directed Discovery of Potent Soluble Epoxide Hydrolase Inhibitors for the Treatment of Inflammatory Diseases. ELISA, LPS, TNF-alpha, VCAM
5  2023 Targeting soluble epoxide hydrolase promotes osteogenic-angiogenic coupling via activating SLIT3/HIF-1α signalling pathway. ECs, EETs, hDPSCs, HUVECs
6  2023 VEGF-A: A NOVEL MECHANISTIC LINK BETWEEN CYP2C-DERIVED EET AND NOX4 IN DIABETIC KIDNEY DISEASE. CYP2C, EET, STZ, T1D, VEGFA
7  2022 A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer's Disease Mice Models. AChE, AD, BDNF, GFAP, IL-6, pCREB, PSD-95, SAMP8, Trem2
8  2022 A Distinct Metabolically Defined Central Nucleus Circuit Bidirectionally Controls Anxiety-Related Behaviors. BNST, CeA, PUFAs
9  2022 A hypothesis-driven study to comprehensively investigate the association between genetic polymorphisms in EPHX2 gene and cardiovascular diseases: Findings from the UK Biobank. CVDs, EETs
10  2022 Adeno-associated virus-mediated invivo suppression of expression of EPHX2 gene modulates the activity of paraventricular nucleus neurons in spontaneously hypertensive rats. Ang II, EETs, GFAP, PVN, SHRs, SR, WKY
11  2022 Aflatoxin B1 exposure disrupts the intestinal immune function via a soluble epoxide hydrolase-mediated manner. AFB1
12  2022 Age-dependent cognitive impairment, hydrocephalus and leukocyte infiltration in transgenic mice with endothelial expression of human EPHX2. CCAO, ED, VCI
13  2022 Anti-Inflammatory Activity of Soluble Epoxide Hydrolase Inhibitors Based on Selenoureas Bearing an Adamantane Moiety. ---
14  2022 Anti-nociceptive efficacy of the soluble epoxide hydrolase inhibitor t-TUCB in horses with mechanically induced lameness. a-HBS, t-TUCB, VAS
15  2022 Cardiomyocyte-specific disruption of soluble epoxide hydrolase limits inflammation to preserve cardiac function. EpFAs, LPS, NLRP3
16  2022 Catechin Reduces Blood Pressure in Spontaneously Hypertensive Rats through Modulation of Arachidonic Acid Metabolism. AA, CAP, CAT, SHR
17  2022 CES2 sustains HNF4alpha expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. CES2, PDAC
18  2022 Compilation and evaluation of a fatty acid mimetics screening library. FAMs, FFAR1, LTA4H, PPARgamma, RXRalpha
19  2022 COX-2/sEH Dual Inhibitor Alleviates Hepatocyte Senescence in NAFLD Mice by Restoring Autophagy through Sirt1/PI3K/AKT/mTOR. ARA, COX-2, HFD, NAFLD, PA
20  2022 COX-2/sEH Dual Inhibitor PTUPB Alleviates CCl 4 -Induced Liver Fibrosis and Portal Hypertension. CK-19, COX-2, eNOS, GCH1, IL-6, PHT, PP, PTUPB, SMA, TGF-beta, VEGF, vWF
21  2022 COX-2/sEH Dual Inhibitor PTUPB Attenuates Epithelial-Mesenchymal Transformation of Alveolar Epithelial Cells via Nrf2-Mediated Inhibition of TGF-β1/Smad Signaling. AECs, alpha-SMA, ARA, BLM, COX-2, EMT, PF, TGF
22  2022 Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response. A1AR, A3AR, AA, CAD, CRH, CVDs, DHETs, EETs, LA, WT
23  2022 CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators. AA, DHETs, EETs
24  2022 Decreased Expression of Soluble Epoxide Hydrolase Suppresses Murine Choroidal Neovascularization. AAV, CNV, nAMD
25  2022 Designing a Small Fluorescent Inhibitor to Investigate Soluble Epoxide Hydrolase Engagement in Living Cells. CNS, NBD-Cl
26  2022 Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. AChE, AD
27  2022 Discovery and Optimization of Indoline-Based Compounds as Dual 5-LOX/sEH Inhibitors: In Vitro and In Vivo Anti-Inflammatory Characterization. 5-LOX
28  2022 Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors. mPGES-1
29  2022 Discovery of benzamide derivatives containing urea moiety as soluble epoxide hydrolase inhibitors. ---
30  2022 Dissecting the Regulation of Arachidonic Acid Metabolites by Uncaria rhynchophylla (Miq). Miq. in Spontaneously Hypertensive Rats and the Predictive Target sEH in the Anti-Hypertensive Effect Based on Metabolomics and Molecular Docking. EETs, SHRs, URE
31  2022 Effects of cyclooxygenase and soluble epoxide hydrolase inhibitors on apoptosis of cultured primary equine chondrocytes. COX, ER
32  2022 Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer's dementia. 5-LOX, AD, APOE4, cPLA2, DPA, EPA, NPD1, ROS
33  2022 Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy. DHETs, EETs, UUO
34  2022 Epoxyeicosatrienoic acids and soluble epoxide hydrolase in physiology and diseases of the central nervous system. CNS, EETs
35  2022 Epoxyeicosatrienoic Acids Inhibit the Activation of Murine Fibroblasts by Blocking the TGF-beta1-Smad2/3 Signaling in a PPARgamma-Dependent Manner. EETs, PF
36  2022 Genetic analyses of circulating PUFA-derived mediators identifies heritable dihydroxyeicosatrienoic acid species. DHET
37  2022 Glimepiride Use is Associated with Reduced Cardiovascular Mortality in Patients with Type 2 Diabetes and Chronic Heart Failure: A Prospective Cohort Study. CHF, CI, EET, HR, T2D
38  2022 Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue. ESRD, HD, LOX
39  2022 Hyperhomocysteinemia dysregulates plasma levels of polyunsaturated fatty acids-derived eicosanoids. AA, COX, CVD, EETs, HHcy, PUFA, WT
40  2022 Identifying simultaneous matrix metalloproteinases/soluble epoxide hydrolase inhibitors. MMP
41  2022 Inhibitors of soluble epoxide hydrolase on acute lung injury: a meta-analysis of preclinical studies. ALI
42  2022 Inhibitory Activity of Quaternary Isoquinoline Alkaloids on Soluble Epoxide Hydrolase. ---
43  2022 Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model. KO, MPTP, PD, SN, STR, TH
44  2022 Machine Learning on DNA-Encoded Library Count Data Using an Uncertainty-Aware Probabilistic Loss Function. DEL, QSAR
45  2022 New pyrimidine/thiazole hybrids endowed with analgesic, anti-inflammatory, and lower cardiotoxic activities: Design, synthesis, and COX-2/sEH dual inhibition. COX
46  2022 Plasma Oxylipins and Their Precursors Are Strongly Associated with COVID-19 Severity and with Immune Response Markers. AA, ICU, LA, PUFA
47  2022 Quinazoline-4(3H)-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition. EETs
48  2022 Redox Regulation of Soluble Epoxide Hydrolase-Implications for Cardiovascular Health and Disease. ---
49  2022 Repositioning of Quinazolinedione-Based Compounds on Soluble Epoxide Hydrolase (sEH) through 3D Structure-Based Pharmacophore Model-Driven Investigation. Hsp90
50  2022 Repurposing of digoxin in pain and inflammation: An evidence-based study. ---
51  2022 Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs. CVD, EETs
52  2022 Role of the soluble epoxide hydrolase in the hair follicle stem cell homeostasis and hair growth. PUFAs
53  2022 Screening and Identification of Novel Soluble Epoxide Hydrolase Inhibitors from Corn Gluten Peptides. ---
54  2022 Sexual dimorphism in renal heme oxygenase-1 and arachidonic acid metabolizing enzymes in spontaneously hypertensive rats versus normotensive Wistar Kyoto rats. 20-HETE, BP, COX-2, CYP4A, EETs, HO, HO-1, PGE2, SHR, TBARS
55  2022 SMTP-44D Exerts Antioxidant and Anti-Inflammatory Effects through Its Soluble Epoxide Hydrolase Inhibitory Action in Immortalized Mouse Schwann Cells upon High Glucose Treatment. DHETs, DN, EETs, RAGE, SMTP-44D
56  2022 Soluble Epoxide Hydrolase Deletion Limits High-Fat Diet-Induced Inflammation. ---
57  2022 Soluble epoxide hydrolase inhibition avoid formalin-induced inflammatory hyperalgesia in the temporomandibular joint. EETs, ELISA, IL-10, TMJ
58  2022 Soluble Epoxide Hydrolase Inhibition Protected against Diabetic Cardiomyopathy through Inducing Autophagy and Reducing Apoptosis Relying on Nrf2 Upregulation and Transcription Activation. DCM, HGHF
59  2022 Soluble Epoxide Hydrolase Inhibitor t-AUCB Ameliorates Vascular Endothelial Dysfunction by Influencing the NF-kappaB/miR-155-5p/eNOS/NO/IkappaB Cycle in Hypertensive Rats. EETs
60  2022 Soluble epoxide hydrolase inhibitor, TPPU, attenuates progression of atherosclerotic lesions and vascular smooth muscle cell phenotypic switching. NOX4, VSMCs
61  2022 Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade. EFAs, sEHIs
62  2022 Soluble Epoxide Hydrolase Is Associated with Postprandial Anxiety Decrease in Healthy Adult Women. AN, BMI, HW
63  2022 Structure-activity relationship studies of benzothiazole-phenyl analogs as multi-target ligands to alleviate pain without affecting normal behavior. FAAH, SAR
64  2022 Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain. ---
65  2022 Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors. ---
66  2022 Synthesis and structure-activity relationships for some novel diflapolin derivatives with benzimidazole subunit. GI, SAR
67  2022 Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors. sEHI
68  2022 Targeting IRE1alpha-JNK-c-Jun/AP-1-sEH Signaling Pathway Improves Myocardial and Coronary Endothelial Function Following Global Myocardial Ischemia/Reperfusion. ER, I/R, LVEDP, LVSP
69  2022 The Modulation of Arachidonic Acid Metabolism and Blood Pressure-Lowering Effect of Honokiol in Spontaneously Hypertensive Rats. AA, Hon, SHR
70  2022 Therapeutic potential of mangiferin against kidney disorders and its mechanism of action: A review. NF-kappaB
71  2022 Unprecedented diterpenoid dimers with soluble epoxide hydrolase inhibitory effect from Euphorbia fischeriana. ---
72  2021 2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity. sEHI
73  2021 A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage. CSF, DCI, DHETs, EETs, SAH
74  2021 A thiol redox sensor in soluble epoxide hydrolase enables oxidative activation by intra-protein disulfide bond formation. DHETs, EETs
75  2021 Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19. sEHIs
76  2021 Activity of sEH and Oxidant Status during Systemic Bovine Coliform Mastitis. ---
77  2021 Adenosine A2A receptor and vascular response: role of soluble epoxide hydrolase, adenosine A1 receptor and angiotensin-II. A1AR, Ang II
78  2021 Adrenic Acid-Derived Epoxy Fatty Acids Are Naturally Occurring Lipids and Their Methyl Ester Prodrug Reduces Endoplasmic Reticulum Stress and Inflammatory Pain. DHDTs, EDTs, EpFAs, ER, PUFA
79  2021 ANTIHYPERTENSIVE AND CARDIOPROTECTIVE EFFECTS OF EPOXYEICOSATRIENOIC ACID ANALOGS AND SOLUBLE EPOXIDE HYDROLASE INHIBITORS (REVIEW). AH, Dss, EETs, sEHI, VE
80  2021 Bisfischoids A and B, dimeric ent-abietane-type diterpenoids with anti-inflammatory potential from Euphorbia fischeriana Steud. ---
81  2021 Cyp2c44 epoxygenase-derived epoxyeicosatrienoic acids in vascular smooth muscle cells elicit vasoconstriction of the murine ophthalmic artery. EETs, VSMC
82  2021 Cytochrome P450-epoxygenated fatty acids inhibit Muller glial inflammation. DR, EDP, EET, MC, PA
83  2021 Deletion of soluble epoxide hydrolase suppressed chronic kidney disease-related vascular calcification by restoring Sirtuin 3 expression. ATP, CKD, CVD, EETs, Sirt3, VSMCs, WT
84  2021 Differential Effects of 17,18-EEQ and 19,20-EDP Combined with Soluble Epoxide Hydrolase Inhibitor t-TUCB on Diet-Induced Obesity in Mice. 19,20-EDP, BAT, TG
85  2021 Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. DIO, FXR, NAFLD, NASH
86  2021 Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis. ---
87  2021 Discovery of novel heterocyclic amide-based inhibitors: an integrative in-silico approach to targeting soluble epoxide hydrolase. ---
88  2021 Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded library technology (ELT). ELT
89  2021 DPP4 inhibitor reduces portal hypertension in cirrhotic rats by normalizing arterial hypocontractility. DPP-4i, EET, NE, NOX, ROS
90  2021 Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity. COX-2
91  2021 EETs/sEHi alleviates nociception by blocking the crosslink between endoplasmic reticulum stress and neuroinflammation in a central poststroke pain model. CPSP, EETs, ER, LPS, MAPK, PWMT, sEHi, VPL
92  2021 Eicosanoid regulation of debris-stimulated metastasis. EP4
93  2021 Endothelial Nox4 dysfunction aggravates atherosclerosis by inducing endoplasmic reticulum stress and soluble epoxide hydrolase. 4-PBA, ECs, ER, TPPU, VCAM-1
94  2021 Epoxyeicosatrienoic Acids and Fibrosis: Recent Insights for the Novel Therapeutic Strategies. ARA, DHETs, EETs
95  2021 Epoxylipids and soluble epoxide hydrolase in heart diseases. ---
96  2021 Evaluating the protective effects of individual or combined ginsenoside compound K and the downregulation of soluble epoxide hydrolase expression against sodium valproate-induced liver cell damage. GCK, SVP
97  2021 First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. PET
98  2021 From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis. sEHIs
99  2021 Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors. EETs, FAAH
100  2021 Genetic deficiency or pharmacological inhibition of soluble epoxide hydrolase ameliorates high fat diet-induced pancreatic beta-cell dysfunction and loss. EETs